Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | HTT | P42858 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | GALR3 | O60755 | 1/20 | 0.53 |
| ▸ | STAT3 | P40763 | 1/20 | 0.53 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | BCHE | P06276 | 1/20 | 0.46 |
| ▸ | TRPC3 | Q13507 | 1/20 | 0.46 |
| ▸ | TRPC4 | Q9UBN4 | 1/20 | 0.46 |
| ▸ | TRPC5 | Q9UL62 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | LTA4H | P09960 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28248398 | 0.89 | NPC1 (0.50) | RAB9ADDAH1NPC1BCHETRPC3 | |
| SCHEMBL2675687 | 0.87 | DDAH1 (0.56) | RAB9AMEN1MAPTHTTKMT2A | |
| Hydrochloric Acid SCHEMBL28081465 | 0.86 | DDAH1 (0.55) | RAB9AMEN1MAPTHTTKMT2A | |
| SCHEMBL23122423 | 0.85 | TSHR (0.49) | RAB9AMAPTDDAH1NPC1KDM4E | |
| SCHEMBL139718 | 0.83 | LTA4H (0.46) | RAB9AMEN1HTTKMT2ADDAH1 | |
| SCHEMBL23123122 | 0.82 | ACHE (0.63) | RAB9ADDAH1NPC1BCHELMNA | |
| Boric Acid SCHEMBL28397024 | 0.79 | LTA4H (0.43) | RAB9AMEN1KMT2ADDAH1NPC1 | |
| SCHEMBL6590211 | 0.79 | LTA4H (0.44) | RAB9AKMT2ANPC1BCHELMNA | |
| SCHEMBL7419107 | 0.79 | SMN1; SMN2 (0.48) | RAB9AMEN1MAPTKMT2ADDAH1 | |
| SCHEMBL132762 | 0.79 | NPC1 (0.48) | RAB9AMEN1HTTKMT2ADDAH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112362783-A | High-flux and rapid screening method for potential pollutants in non-medicines for fishing | 江苏省淡水水产研究所 | 2021-02-12 | — | — | CN | claimed |
| CN-114814013-A | Method for rapidly screening unknown chemical hazard residues in aquatic products based on high-resolution mass spectrum database | 中国海洋大学 | 2022-07-29 | — | — | CN | disclosed |
| CN-113081968-A | Oral gel powder for treating livestock and poultry diseases and preparation method thereof | 泰州骏道立同生物科技有限公司 | 2021-07-09 | — | — | CN | disclosed |
| CN-112362783-A | High-flux and rapid screening method for potential pollutants in non-medicines for fishing | 江苏省淡水水产研究所 | 2021-02-12 | — | — | CN | disclosed |
| CN-103930549-B | Methods and compositions for weed control | 孟山都技术公司 | 2020-09-18 | — | — | CN | disclosed |
| CN-103958539-B | Methods and compositions for weed control | 孟山都技术公司 | 2019-12-17 | — | — | CN | disclosed |
| US-7538133-B2 | Benzimidazole derivatives, their production and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-05-26 | — | — | US | disclosed |
| US-20070259932-A1 | angiotensin II antagonists; Hypotensive agents; cardiovascular disorders; reacting Ethyl 1-[(2'-cyanobiphenyl-4-yl)methyl]-2-mercaptobenzimidazole-7-carboxylic acid compound with alkylating agent | TAKEDA PHARMACEUTICAL COMPANY, LIMITED | 2007-11-08 | — | — | US | disclosed |
| US-7153972-B2 | Benzimidazole derivatives, their production and use | TAKEDA PHARMACEUTICAL COMPANY, LIMITED (JP) | 2006-12-26 | — | — | US | disclosed |
| US-20050131039-A1 | Benzimidazole derivatives, their production and use | TAKEDA CHEMICAL INDUSTRIES, LTD. | 2005-06-16 | — | — | US | disclosed |
| US-20020151723-A1 | Benzimidazole derivatives, their production and use | TAKEDA CHEMICAL INDUSTRIES, LTD. | 2002-10-17 | — | — | US | disclosed |
| US-6355808-B2 | ANGAGONIZING ANGIOTENSIN II | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2002-03-12 | — | — | US | disclosed |
| US-20010047020-A1 | Benzimidazole derivatives, their production and use | TAKEDA PHARAMCEUTICAL COMPANY, LIMITED (JP) | 2001-11-29 | — | — | US | disclosed |
| US-6232334-B1 | HAVE POTENT ANGIOTENSIN II ANTAGONISTIC ACTIVITY AND ANTIHYPERTENSIVE ACTIVITY, FOR TREATING CIRCULATORY SYSTEM DISEASES SUCH AS HYPERTENSIVE DISEASES, HEART DISEASES, STROKES, CEREBRAL APOPLEXY AND NEPHRITIS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-05-15 | — | — | US | disclosed |
| US-6004989-A | ETHYL 2-ETHOXY-1-(2'-1H-TETRAZOL-5-YL)BIPHENYL-4-YL)METHYL) BENZIMIDAZOLE-7-CARBOXYLATE AND SALTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1999-12-21 | — | — | US | disclosed |
| US-5962491-A | ANGIOTENSIN ANTAGONIST, HYPOTENSIVE AGENTS, CARDIOVASCULAR DISORDERS, STROKES | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1999-10-05 | — | — | US | disclosed |
| US-5705517-A | ANGIOTENSIN II ANTAGONISTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1998-01-06 | — | — | US | disclosed |
| US-5703110-A | HYPOTENSIVE AGENTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1997-12-30 | — | — | US | disclosed |
| EP-0720982-A1 | Benzimidazole derivatives, their production and use and use as angiotensin II antagonists | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1996-07-10 | — | — | EP | disclosed |
| EP-0459136-A1 | Benzimidazole derivatives, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1991-12-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259932-A1 | angiotensin II antagonists; Hypotensive agents; cardiovascular disorders; reacting Ethyl 1-[(2'-cyanobiphenyl-4-yl)methyl]-2-mercaptobenzimidazole-7-carboxylic acid compound with alkylating agent | AGTR1, REN, AGTR2 | RAB9A 3848/4885MEN1 136/4885MAPT 4835/4885 |
| US-20050131039-A1 | Benzimidazole derivatives, their production and use | MRM1, CARM1, H1-4 | RAB9A 3767/4885MEN1 1169/4885MAPT 4582/4885 |
| US-20020151723-A1 | Benzimidazole derivatives, their production and use | HAT1, MRM1, NSD1 | RAB9A 4132/4885MEN1 1449/4885MAPT 4622/4885 |
| US-20010047020-A1 | Benzimidazole derivatives, their production and use | REN, AGTR1, H1-3 | RAB9A 3790/4885MEN1 1078/4885MAPT 4451/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.